660 related articles for article (PubMed ID: 22630093)
41. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
42. Occurrence and sensitivity profile of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary hospital in Southern Brazil.
Rugini CL; Sobottka AM; Fuentefria DB
Rev Soc Bras Med Trop; 2015; 48(6):692-8. PubMed ID: 26676493
[TBL] [Abstract][Full Text] [Related]
43. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
44. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
45. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Melchers MJ; van Mil AC; Mouton JW
Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
[TBL] [Abstract][Full Text] [Related]
46. Extended-spectrum-beta-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon.
Gangoué-Piéboji J; Bedenic B; Koulla-Shiro S; Randegger C; Adiogo D; Ngassam P; Ndumbe P; Hächler H
J Clin Microbiol; 2005 Jul; 43(7):3273-7. PubMed ID: 16000447
[TBL] [Abstract][Full Text] [Related]
47. Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
Bert F; Larroque B; Dondero F; Durand F; Paugam-Burtz C; Belghiti J; Moreau R; Nicolas-Chanoine MH
Transpl Infect Dis; 2014 Feb; 16(1):84-9. PubMed ID: 24330161
[TBL] [Abstract][Full Text] [Related]
48. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
49. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
[TBL] [Abstract][Full Text] [Related]
50. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
51. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Pagani L; Migliavacca R; Luzzaro F; Giacobone E; Perilli M; Micheletti P; Amicosante G
Chemotherapy; 1998; 44(6):377-84. PubMed ID: 9755296
[TBL] [Abstract][Full Text] [Related]
52. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
[TBL] [Abstract][Full Text] [Related]
53. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
54. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
55. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
[TBL] [Abstract][Full Text] [Related]
56. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
57. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
[TBL] [Abstract][Full Text] [Related]
58. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Vardi M; Kochavi T; Denekamp Y; Bitterman H
Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
[TBL] [Abstract][Full Text] [Related]
59. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
[TBL] [Abstract][Full Text] [Related]
60. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
